NewsConcerns explains that Molnupiravir, Merck’s new anti-viral, has issues with both efficacy and safety.
FLCCC founder and Chief Medical Officer, Dr. Pierre Kory, talked to Eric Bolling on The Balance and compared Merck's "COVID pill" to ivermectin.